Iambic Therapeutics (NASDAQ:IAM) Posts Quarterly Earnings Results, Misses Expectations By $5.90 EPS

Iambic Therapeutics (NASDAQ:IAM – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($6.23) EPS for the quarter, missing the consensus estimate of ($0.33) by ($5.90), Zacks reports.

Iambic Therapeutics Stock Down 12.4%

Shares of IAM traded down $1.62 during midday trading on Monday, reaching $11.48. The company had a trading volume of 110,258 shares, compared to its average volume of 702,804. Iambic Therapeutics has a 1-year low of $9.60 and a 1-year high of $25.00.

Insider Buying and Selling at Iambic Therapeutics

In other news, Director Evan Lockwood Rachlin purchased 718,750 shares of the stock in a transaction dated Friday, October 16th. The shares were purchased at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the transaction, the director owned 2,588,248 shares in the company, valued at $41,411,968. The trade was a 38.45% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IAM. Jefferies Financial Group assumed coverage on shares of Iambic Therapeutics in a research note on Tuesday, November 10th. They set a “buy” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. began coverage on shares of Iambic Therapeutics in a report on Monday, November 9th. They set an “overweight” rating and a $22.00 target price for the company. Wall Street Zen upgraded shares of Iambic Therapeutics to a “hold” rating in a research report on Saturday, November 7th. Zacks Research assumed coverage on shares of Iambic Therapeutics in a research note on Tuesday, November 10th. They issued a “hold” rating on the stock. Finally, Bank of America began coverage on shares of Iambic Therapeutics in a research report on Monday, November 9th. They set a “buy” rating and a $30.00 price target on the stock. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.25.

Read Our Latest Research Report on IAM

About Iambic Therapeutics

(Get Free Report)

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.

Read More

Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.